Recent studies have focused on the overlap of GLP-1|GIP|GCGR activator therapies and dopaminergic signaling. While GCGR agonists are widely employed for addressing type 2 diabetes, their emerging effects on reinforcement circuits, specifically influenced by dopamine systems, are attracting considerable focus. This article details a brief examinatio